nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—ABCB1—esophageal cancer	0.406	1	CbGaD
Haloperidol—Sudden death, cause unknown—Capecitabine—esophageal cancer	0.0102	0.064	CcSEcCtD
Haloperidol—Motor dysfunction—Methotrexate—esophageal cancer	0.00708	0.0444	CcSEcCtD
Haloperidol—HTR2A—vagus nerve—esophageal cancer	0.00646	0.0854	CbGeAlD
Haloperidol—Trismus—Capecitabine—esophageal cancer	0.00414	0.026	CcSEcCtD
Haloperidol—H1F0—neck—esophageal cancer	0.00368	0.0487	CbGeAlD
Haloperidol—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.00322	0.0202	CcSEcCtD
Haloperidol—UGT1A9—digestive system—esophageal cancer	0.00309	0.0409	CbGeAlD
Haloperidol—CBR1—bronchus—esophageal cancer	0.00301	0.0398	CbGeAlD
Haloperidol—Retinal disorder—Methotrexate—esophageal cancer	0.00288	0.0181	CcSEcCtD
Haloperidol—CBR1—trachea—esophageal cancer	0.0027	0.0358	CbGeAlD
Haloperidol—Sudden death—Capecitabine—esophageal cancer	0.0027	0.0169	CcSEcCtD
Haloperidol—H1F0—bronchus—esophageal cancer	0.00247	0.0326	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—esophageal cancer	0.00241	0.0319	CbGeAlD
Haloperidol—CBR1—digestive system—esophageal cancer	0.00233	0.0308	CbGeAlD
Haloperidol—Loss of libido—Methotrexate—esophageal cancer	0.00223	0.014	CcSEcCtD
Haloperidol—H1F0—trachea—esophageal cancer	0.00221	0.0293	CbGeAlD
Haloperidol—Leukocytoclastic vasculitis—Methotrexate—esophageal cancer	0.0021	0.0131	CcSEcCtD
Haloperidol—Sudden death—Methotrexate—esophageal cancer	0.00201	0.0126	CcSEcCtD
Haloperidol—Torsade de pointes—Capecitabine—esophageal cancer	0.00197	0.0124	CcSEcCtD
Haloperidol—CBR1—lung—esophageal cancer	0.00194	0.0257	CbGeAlD
Haloperidol—H1F0—digestive system—esophageal cancer	0.00191	0.0252	CbGeAlD
Haloperidol—Ventricular fibrillation—Capecitabine—esophageal cancer	0.0018	0.0113	CcSEcCtD
Haloperidol—Body temperature increased—Carboplatin—esophageal cancer	0.0018	0.0113	CcSEcCtD
Haloperidol—SIGMAR1—bronchus—esophageal cancer	0.00178	0.0236	CbGeAlD
Haloperidol—SIGMAR1—smooth muscle tissue—esophageal cancer	0.00174	0.0231	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—esophageal cancer	0.00174	0.023	CbGeAlD
Haloperidol—Extrasystoles—Capecitabine—esophageal cancer	0.00164	0.0103	CcSEcCtD
Haloperidol—SIGMAR1—trachea—esophageal cancer	0.0016	0.0212	CbGeAlD
Haloperidol—H1F0—lung—esophageal cancer	0.00159	0.021	CbGeAlD
Haloperidol—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00154	0.00966	CcSEcCtD
Haloperidol—Cataract—Capecitabine—esophageal cancer	0.00145	0.0091	CcSEcCtD
Haloperidol—HTR2A—neck—esophageal cancer	0.00142	0.0187	CbGeAlD
Haloperidol—Gait disturbance—Capecitabine—esophageal cancer	0.00141	0.00888	CcSEcCtD
Haloperidol—HTR2B—digestive system—esophageal cancer	0.00137	0.0182	CbGeAlD
Haloperidol—Injection site reaction—Capecitabine—esophageal cancer	0.00137	0.00861	CcSEcCtD
Haloperidol—Hyponatraemia—Cisplatin—esophageal cancer	0.00136	0.00856	CcSEcCtD
Haloperidol—CBR1—lymph node—esophageal cancer	0.00133	0.0176	CbGeAlD
Haloperidol—Face oedema—Cisplatin—esophageal cancer	0.00131	0.00824	CcSEcCtD
Haloperidol—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00124	0.00779	CcSEcCtD
Haloperidol—Breast disorder—Cisplatin—esophageal cancer	0.00123	0.00771	CcSEcCtD
Haloperidol—CYP1A1—epithelium—esophageal cancer	0.00122	0.0161	CbGeAlD
Haloperidol—CYP1A1—bronchus—esophageal cancer	0.0012	0.0158	CbGeAlD
Haloperidol—HRH1—epithelium—esophageal cancer	0.00115	0.0153	CbGeAlD
Haloperidol—SIGMAR1—lung—esophageal cancer	0.00115	0.0152	CbGeAlD
Haloperidol—CYP2C19—digestive system—esophageal cancer	0.00115	0.0152	CbGeAlD
Haloperidol—HTR2B—lung—esophageal cancer	0.00115	0.0152	CbGeAlD
Haloperidol—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00115	0.0072	CcSEcCtD
Haloperidol—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00115	0.00719	CcSEcCtD
Haloperidol—Sweating increased—Cisplatin—esophageal cancer	0.00114	0.00718	CcSEcCtD
Haloperidol—Photosensitivity—Capecitabine—esophageal cancer	0.00114	0.00716	CcSEcCtD
Haloperidol—Pancytopenia—Cisplatin—esophageal cancer	0.00112	0.007	CcSEcCtD
Haloperidol—HRH1—smooth muscle tissue—esophageal cancer	0.00111	0.0147	CbGeAlD
Haloperidol—H1F0—lymph node—esophageal cancer	0.00109	0.0144	CbGeAlD
Haloperidol—Libido decreased—Capecitabine—esophageal cancer	0.00108	0.00678	CcSEcCtD
Haloperidol—CYP1A1—trachea—esophageal cancer	0.00108	0.0142	CbGeAlD
Haloperidol—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00106	0.00666	CcSEcCtD
Haloperidol—Lethargy—Capecitabine—esophageal cancer	0.00102	0.00642	CcSEcCtD
Haloperidol—HRH1—trachea—esophageal cancer	0.00102	0.0135	CbGeAlD
Haloperidol—Hyponatraemia—Capecitabine—esophageal cancer	0.00101	0.00631	CcSEcCtD
Haloperidol—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000994	0.00624	CcSEcCtD
Haloperidol—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000991	0.00622	CcSEcCtD
Haloperidol—Face oedema—Capecitabine—esophageal cancer	0.000967	0.00607	CcSEcCtD
Haloperidol—HTR2A—epithelium—esophageal cancer	0.000964	0.0127	CbGeAlD
Haloperidol—Urinary retention—Capecitabine—esophageal cancer	0.000953	0.00598	CcSEcCtD
Haloperidol—Cardiac arrest—Capecitabine—esophageal cancer	0.000953	0.00598	CcSEcCtD
Haloperidol—CYP1A2—digestive system—esophageal cancer	0.000938	0.0124	CbGeAlD
Haloperidol—Urinary tract disorder—Cisplatin—esophageal cancer	0.000929	0.00583	CcSEcCtD
Haloperidol—HTR2A—smooth muscle tissue—esophageal cancer	0.000929	0.0123	CbGeAlD
Haloperidol—DRD2—lung—esophageal cancer	0.000928	0.0123	CbGeAlD
Haloperidol—Liver function test abnormal—Capecitabine—esophageal cancer	0.000925	0.00581	CcSEcCtD
Haloperidol—CYP1A1—digestive system—esophageal cancer	0.000925	0.0122	CbGeAlD
Haloperidol—Connective tissue disorder—Cisplatin—esophageal cancer	0.000924	0.0058	CcSEcCtD
Haloperidol—Urethral disorder—Cisplatin—esophageal cancer	0.000922	0.00578	CcSEcCtD
Haloperidol—Gynaecomastia—Methotrexate—esophageal cancer	0.000919	0.00577	CcSEcCtD
Haloperidol—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000915	0.00574	CcSEcCtD
Haloperidol—Visual impairment—Cisplatin—esophageal cancer	0.000906	0.00569	CcSEcCtD
Haloperidol—Breast disorder—Capecitabine—esophageal cancer	0.000905	0.00568	CcSEcCtD
Haloperidol—CYP3A5—digestive system—esophageal cancer	0.000904	0.012	CbGeAlD
Haloperidol—CYP2C9—digestive system—esophageal cancer	0.00089	0.0118	CbGeAlD
Haloperidol—Eye disorder—Cisplatin—esophageal cancer	0.000879	0.00551	CcSEcCtD
Haloperidol—HRH1—digestive system—esophageal cancer	0.000878	0.0116	CbGeAlD
Haloperidol—Cardiac disorder—Cisplatin—esophageal cancer	0.000873	0.00548	CcSEcCtD
Haloperidol—Dysphagia—Capecitabine—esophageal cancer	0.000866	0.00543	CcSEcCtD
Haloperidol—HTR2A—trachea—esophageal cancer	0.000852	0.0113	CbGeAlD
Haloperidol—Bronchospasm—Capecitabine—esophageal cancer	0.000852	0.00535	CcSEcCtD
Haloperidol—Photosensitivity—Methotrexate—esophageal cancer	0.00085	0.00533	CcSEcCtD
Haloperidol—Immune system disorder—Cisplatin—esophageal cancer	0.000849	0.00533	CcSEcCtD
Haloperidol—Mediastinal disorder—Cisplatin—esophageal cancer	0.000848	0.00532	CcSEcCtD
Haloperidol—Sweating increased—Capecitabine—esophageal cancer	0.000844	0.00529	CcSEcCtD
Haloperidol—Alopecia—Cisplatin—esophageal cancer	0.000831	0.00521	CcSEcCtD
Haloperidol—Pancytopenia—Capecitabine—esophageal cancer	0.000822	0.00516	CcSEcCtD
Haloperidol—Malnutrition—Cisplatin—esophageal cancer	0.000819	0.00514	CcSEcCtD
Haloperidol—Neutropenia—Capecitabine—esophageal cancer	0.00081	0.00508	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000791	0.00496	CcSEcCtD
Haloperidol—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00079	0.00496	CcSEcCtD
Haloperidol—Weight increased—Capecitabine—esophageal cancer	0.000788	0.00495	CcSEcCtD
Haloperidol—Visual disturbance—Methotrexate—esophageal cancer	0.000787	0.00494	CcSEcCtD
Haloperidol—Muscle spasms—Cisplatin—esophageal cancer	0.000787	0.00494	CcSEcCtD
Haloperidol—SIGMAR1—lymph node—esophageal cancer	0.000786	0.0104	CbGeAlD
Haloperidol—HTR2B—lymph node—esophageal cancer	0.000784	0.0104	CbGeAlD
Haloperidol—Weight decreased—Capecitabine—esophageal cancer	0.000784	0.00492	CcSEcCtD
Haloperidol—CYP1A2—lung—esophageal cancer	0.000783	0.0104	CbGeAlD
Haloperidol—Hyperglycaemia—Capecitabine—esophageal cancer	0.000781	0.0049	CcSEcCtD
Haloperidol—CYP1A1—lung—esophageal cancer	0.000772	0.0102	CbGeAlD
Haloperidol—Vision blurred—Cisplatin—esophageal cancer	0.000771	0.00484	CcSEcCtD
Haloperidol—Depression—Capecitabine—esophageal cancer	0.00077	0.00483	CcSEcCtD
Haloperidol—Tremor—Cisplatin—esophageal cancer	0.000767	0.00481	CcSEcCtD
Haloperidol—Lethargy—Methotrexate—esophageal cancer	0.000761	0.00478	CcSEcCtD
Haloperidol—Anaemia—Cisplatin—esophageal cancer	0.000757	0.00475	CcSEcCtD
Haloperidol—CYP3A5—lung—esophageal cancer	0.000755	0.00999	CbGeAlD
Haloperidol—Jaundice—Capecitabine—esophageal cancer	0.000753	0.00472	CcSEcCtD
Haloperidol—HTR2A—digestive system—esophageal cancer	0.000733	0.0097	CbGeAlD
Haloperidol—HRH1—lung—esophageal cancer	0.000733	0.0097	CbGeAlD
Haloperidol—Leukopenia—Cisplatin—esophageal cancer	0.000733	0.0046	CcSEcCtD
Haloperidol—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00073	0.00458	CcSEcCtD
Haloperidol—Agranulocytosis—Capecitabine—esophageal cancer	0.000721	0.00452	CcSEcCtD
Haloperidol—Convulsion—Cisplatin—esophageal cancer	0.000709	0.00445	CcSEcCtD
Haloperidol—Anxiety—Cisplatin—esophageal cancer	0.000695	0.00436	CcSEcCtD
Haloperidol—Hepatitis—Capecitabine—esophageal cancer	0.000693	0.00435	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000692	0.00434	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—esophageal cancer	0.000689	0.00432	CcSEcCtD
Haloperidol—Urinary tract disorder—Capecitabine—esophageal cancer	0.000685	0.0043	CcSEcCtD
Haloperidol—Connective tissue disorder—Capecitabine—esophageal cancer	0.000681	0.00427	CcSEcCtD
Haloperidol—Urethral disorder—Capecitabine—esophageal cancer	0.00068	0.00426	CcSEcCtD
Haloperidol—CYP3A4—digestive system—esophageal cancer	0.000679	0.00898	CbGeAlD
Haloperidol—Breast disorder—Methotrexate—esophageal cancer	0.000674	0.00423	CcSEcCtD
Haloperidol—Oedema—Cisplatin—esophageal cancer	0.000668	0.00419	CcSEcCtD
Haloperidol—Anaphylactic shock—Cisplatin—esophageal cancer	0.000668	0.00419	CcSEcCtD
Haloperidol—Visual impairment—Capecitabine—esophageal cancer	0.000668	0.00419	CcSEcCtD
Haloperidol—CYP2D6—digestive system—esophageal cancer	0.000668	0.00884	CbGeAlD
Haloperidol—Nervous system disorder—Cisplatin—esophageal cancer	0.000655	0.00411	CcSEcCtD
Haloperidol—Thrombocytopenia—Cisplatin—esophageal cancer	0.000654	0.00411	CcSEcCtD
Haloperidol—Tachycardia—Cisplatin—esophageal cancer	0.000652	0.00409	CcSEcCtD
Haloperidol—Skin disorder—Cisplatin—esophageal cancer	0.000649	0.00407	CcSEcCtD
Haloperidol—Eye disorder—Capecitabine—esophageal cancer	0.000648	0.00407	CcSEcCtD
Haloperidol—Hyperhidrosis—Cisplatin—esophageal cancer	0.000646	0.00405	CcSEcCtD
Haloperidol—Cardiac disorder—Capecitabine—esophageal cancer	0.000643	0.00404	CcSEcCtD
Haloperidol—Anorexia—Cisplatin—esophageal cancer	0.000637	0.004	CcSEcCtD
Haloperidol—ABCB1—epithelium—esophageal cancer	0.000631	0.00835	CbGeAlD
Haloperidol—Angiopathy—Capecitabine—esophageal cancer	0.000629	0.00395	CcSEcCtD
Haloperidol—Immune system disorder—Capecitabine—esophageal cancer	0.000626	0.00393	CcSEcCtD
Haloperidol—KCNH2—lymph node—esophageal cancer	0.000626	0.00828	CbGeAlD
Haloperidol—Mediastinal disorder—Capecitabine—esophageal cancer	0.000625	0.00392	CcSEcCtD
Haloperidol—Hypotension—Cisplatin—esophageal cancer	0.000624	0.00392	CcSEcCtD
Haloperidol—Alopecia—Capecitabine—esophageal cancer	0.000613	0.00384	CcSEcCtD
Haloperidol—HTR2A—lung—esophageal cancer	0.000612	0.0081	CbGeAlD
Haloperidol—Pancytopenia—Methotrexate—esophageal cancer	0.000612	0.00384	CcSEcCtD
Haloperidol—Mental disorder—Capecitabine—esophageal cancer	0.000607	0.00381	CcSEcCtD
Haloperidol—Malnutrition—Capecitabine—esophageal cancer	0.000603	0.00379	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—esophageal cancer	0.000603	0.00378	CcSEcCtD
Haloperidol—Dyspnoea—Cisplatin—esophageal cancer	0.000596	0.00374	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—esophageal cancer	0.000594	0.00373	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000588	0.00369	CcSEcCtD
Haloperidol—Decreased appetite—Cisplatin—esophageal cancer	0.000581	0.00364	CcSEcCtD
Haloperidol—Muscle spasms—Capecitabine—esophageal cancer	0.00058	0.00364	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000577	0.00362	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—esophageal cancer	0.000575	0.00361	CcSEcCtD
Haloperidol—Depression—Methotrexate—esophageal cancer	0.000573	0.0036	CcSEcCtD
Haloperidol—Vision blurred—Capecitabine—esophageal cancer	0.000569	0.00357	CcSEcCtD
Haloperidol—Tremor—Capecitabine—esophageal cancer	0.000565	0.00355	CcSEcCtD
Haloperidol—ABCB1—trachea—esophageal cancer	0.000558	0.00739	CbGeAlD
Haloperidol—Anaemia—Capecitabine—esophageal cancer	0.000558	0.0035	CcSEcCtD
Haloperidol—Feeling abnormal—Cisplatin—esophageal cancer	0.000551	0.00345	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000544	0.00341	CcSEcCtD
Haloperidol—Vertigo—Capecitabine—esophageal cancer	0.000542	0.0034	CcSEcCtD
Haloperidol—Leukopenia—Capecitabine—esophageal cancer	0.00054	0.00339	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—esophageal cancer	0.000536	0.00337	CcSEcCtD
Haloperidol—CYP1A1—lymph node—esophageal cancer	0.000528	0.00699	CbGeAlD
Haloperidol—Body temperature increased—Cisplatin—esophageal cancer	0.000528	0.00331	CcSEcCtD
Haloperidol—Hypertension—Capecitabine—esophageal cancer	0.000521	0.00327	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—esophageal cancer	0.000516	0.00324	CcSEcCtD
Haloperidol—Anxiety—Capecitabine—esophageal cancer	0.000512	0.00321	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00051	0.0032	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—esophageal cancer	0.00051	0.0032	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—esophageal cancer	0.000506	0.00317	CcSEcCtD
Haloperidol—Dry mouth—Capecitabine—esophageal cancer	0.000502	0.00315	CcSEcCtD
Haloperidol—HRH1—lymph node—esophageal cancer	0.000501	0.00663	CbGeAlD
Haloperidol—Visual impairment—Methotrexate—esophageal cancer	0.000497	0.00312	CcSEcCtD
Haloperidol—Confusional state—Capecitabine—esophageal cancer	0.000497	0.00312	CcSEcCtD
Haloperidol—Oedema—Capecitabine—esophageal cancer	0.000492	0.00309	CcSEcCtD
Haloperidol—Hypersensitivity—Cisplatin—esophageal cancer	0.000492	0.00309	CcSEcCtD
Haloperidol—Nervous system disorder—Capecitabine—esophageal cancer	0.000483	0.00303	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—esophageal cancer	0.000482	0.00303	CcSEcCtD
Haloperidol—Thrombocytopenia—Capecitabine—esophageal cancer	0.000482	0.00303	CcSEcCtD
Haloperidol—Tachycardia—Capecitabine—esophageal cancer	0.000481	0.00302	CcSEcCtD
Haloperidol—ABCB1—digestive system—esophageal cancer	0.00048	0.00636	CbGeAlD
Haloperidol—Cardiac disorder—Methotrexate—esophageal cancer	0.000479	0.00301	CcSEcCtD
Haloperidol—Skin disorder—Capecitabine—esophageal cancer	0.000478	0.003	CcSEcCtD
Haloperidol—Hyperhidrosis—Capecitabine—esophageal cancer	0.000476	0.00299	CcSEcCtD
Haloperidol—Anorexia—Capecitabine—esophageal cancer	0.000469	0.00295	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—esophageal cancer	0.000468	0.00294	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—esophageal cancer	0.000466	0.00293	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000465	0.00292	CcSEcCtD
Haloperidol—Hypotension—Capecitabine—esophageal cancer	0.00046	0.00289	CcSEcCtD
Haloperidol—Diarrhoea—Cisplatin—esophageal cancer	0.000457	0.00287	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—esophageal cancer	0.000456	0.00286	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—esophageal cancer	0.000452	0.00284	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—esophageal cancer	0.000449	0.00282	CcSEcCtD
Haloperidol—Insomnia—Capecitabine—esophageal cancer	0.000445	0.0028	CcSEcCtD
Haloperidol—Dyspnoea—Capecitabine—esophageal cancer	0.000439	0.00276	CcSEcCtD
Haloperidol—Dyspepsia—Capecitabine—esophageal cancer	0.000434	0.00272	CcSEcCtD
Haloperidol—Decreased appetite—Capecitabine—esophageal cancer	0.000428	0.00269	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000425	0.00267	CcSEcCtD
Haloperidol—Vomiting—Cisplatin—esophageal cancer	0.000425	0.00267	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—esophageal cancer	0.000423	0.00266	CcSEcCtD
Haloperidol—Rash—Cisplatin—esophageal cancer	0.000421	0.00264	CcSEcCtD
Haloperidol—Constipation—Capecitabine—esophageal cancer	0.000421	0.00264	CcSEcCtD
Haloperidol—Dermatitis—Cisplatin—esophageal cancer	0.000421	0.00264	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—esophageal cancer	0.000415	0.00261	CcSEcCtD
Haloperidol—Feeling abnormal—Capecitabine—esophageal cancer	0.000406	0.00255	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—esophageal cancer	0.000404	0.00253	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—esophageal cancer	0.000402	0.00252	CcSEcCtD
Haloperidol—ABCB1—lung—esophageal cancer	0.000401	0.00531	CbGeAlD
Haloperidol—Nausea—Cisplatin—esophageal cancer	0.000397	0.00249	CcSEcCtD
Haloperidol—Urticaria—Capecitabine—esophageal cancer	0.000391	0.00246	CcSEcCtD
Haloperidol—Body temperature increased—Capecitabine—esophageal cancer	0.000389	0.00244	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—esophageal cancer	0.000389	0.00244	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00038	0.00238	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—esophageal cancer	0.00037	0.00232	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—esophageal cancer	0.000367	0.0023	CcSEcCtD
Haloperidol—Hypersensitivity—Capecitabine—esophageal cancer	0.000363	0.00228	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—esophageal cancer	0.00036	0.00226	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—esophageal cancer	0.000359	0.00225	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—esophageal cancer	0.000356	0.00223	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000354	0.00222	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—esophageal cancer	0.000349	0.00219	CcSEcCtD
Haloperidol—Pruritus—Capecitabine—esophageal cancer	0.000348	0.00219	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—esophageal cancer	0.000343	0.00215	CcSEcCtD
Haloperidol—Diarrhoea—Capecitabine—esophageal cancer	0.000337	0.00211	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—esophageal cancer	0.000332	0.00208	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—esophageal cancer	0.000327	0.00205	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—esophageal cancer	0.000326	0.00205	CcSEcCtD
Haloperidol—Dizziness—Capecitabine—esophageal cancer	0.000326	0.00204	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—esophageal cancer	0.000323	0.00203	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—esophageal cancer	0.000319	0.002	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000317	0.00199	CcSEcCtD
Haloperidol—Vomiting—Capecitabine—esophageal cancer	0.000313	0.00197	CcSEcCtD
Haloperidol—Rash—Capecitabine—esophageal cancer	0.000311	0.00195	CcSEcCtD
Haloperidol—Dermatitis—Capecitabine—esophageal cancer	0.00031	0.00195	CcSEcCtD
Haloperidol—Headache—Capecitabine—esophageal cancer	0.000309	0.00194	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—esophageal cancer	0.000302	0.0019	CcSEcCtD
Haloperidol—Nausea—Capecitabine—esophageal cancer	0.000293	0.00184	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—esophageal cancer	0.000291	0.00183	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—esophageal cancer	0.00029	0.00182	CcSEcCtD
Haloperidol—ABCB1—lymph node—esophageal cancer	0.000274	0.00363	CbGeAlD
Haloperidol—Hypersensitivity—Methotrexate—esophageal cancer	0.00027	0.0017	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—esophageal cancer	0.000259	0.00163	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—esophageal cancer	0.000251	0.00157	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—esophageal cancer	0.000242	0.00152	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—esophageal cancer	0.000233	0.00146	CcSEcCtD
Haloperidol—Rash—Methotrexate—esophageal cancer	0.000231	0.00145	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—esophageal cancer	0.000231	0.00145	CcSEcCtD
Haloperidol—Headache—Methotrexate—esophageal cancer	0.00023	0.00144	CcSEcCtD
Haloperidol—Nausea—Methotrexate—esophageal cancer	0.000218	0.00137	CcSEcCtD
Haloperidol—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	1.98e-05	5.51e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GNG7—esophageal cancer	1.96e-05	5.46e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	1.94e-05	5.42e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SMAD4—esophageal cancer	1.94e-05	5.4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CREBBP—esophageal cancer	1.94e-05	5.4e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.93e-05	5.38e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ENO1—esophageal cancer	1.93e-05	5.38e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMP—esophageal cancer	1.92e-05	5.35e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.92e-05	5.34e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ENO1—esophageal cancer	1.92e-05	5.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	1.91e-05	5.31e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CREBBP—esophageal cancer	1.91e-05	5.31e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—EGFR—esophageal cancer	1.9e-05	5.3e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SMAD4—esophageal cancer	1.9e-05	5.3e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PSME2—esophageal cancer	1.9e-05	5.3e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PSME1—esophageal cancer	1.9e-05	5.3e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.9e-05	5.3e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NOTCH1—esophageal cancer	1.89e-05	5.27e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PSME2—esophageal cancer	1.89e-05	5.26e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PSME1—esophageal cancer	1.89e-05	5.26e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—EGFR—esophageal cancer	1.87e-05	5.22e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.87e-05	5.22e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—NOS3—esophageal cancer	1.87e-05	5.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.87e-05	5.21e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NOTCH1—esophageal cancer	1.87e-05	5.2e-05	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	1.86e-05	5.18e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.84e-05	5.12e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.84e-05	5.12e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.82e-05	5.08e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CREBBP—esophageal cancer	1.82e-05	5.07e-05	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.82e-05	5.07e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.81e-05	5.03e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ABCB1—esophageal cancer	1.8e-05	5.01e-05	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—PIK3CA—esophageal cancer	1.79e-05	4.99e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—EGFR—esophageal cancer	1.79e-05	4.98e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.79e-05	4.98e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NOS3—esophageal cancer	1.77e-05	4.94e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CREBBP—esophageal cancer	1.76e-05	4.9e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.75e-05	4.87e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.74e-05	4.86e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TPI1—esophageal cancer	1.74e-05	4.84e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.74e-05	4.84e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NOS3—esophageal cancer	1.74e-05	4.83e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.73e-05	4.81e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.72e-05	4.79e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CREBBP—esophageal cancer	1.72e-05	4.78e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—esophageal cancer	1.71e-05	4.77e-05	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.71e-05	4.76e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NOS3—esophageal cancer	1.71e-05	4.76e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CREBBP—esophageal cancer	1.69e-05	4.72e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	1.69e-05	4.7e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—EGFR—esophageal cancer	1.69e-05	4.7e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.68e-05	4.68e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.67e-05	4.64e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—EGFR—esophageal cancer	1.66e-05	4.64e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	1.66e-05	4.62e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.65e-05	4.6e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.65e-05	4.59e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.64e-05	4.58e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.64e-05	4.57e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.64e-05	4.56e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ENO1—esophageal cancer	1.64e-05	4.56e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NOS3—esophageal cancer	1.63e-05	4.54e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.63e-05	4.54e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—PIK3CA—esophageal cancer	1.63e-05	4.53e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ERBB2—esophageal cancer	1.62e-05	4.52e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PSME1—esophageal cancer	1.61e-05	4.49e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PSME2—esophageal cancer	1.61e-05	4.49e-05	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.61e-05	4.49e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.6e-05	4.47e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ERBB2—esophageal cancer	1.6e-05	4.45e-05	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—PIK3CA—esophageal cancer	1.59e-05	4.43e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.59e-05	4.43e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HIF1A—esophageal cancer	1.59e-05	4.42e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—NOS3—esophageal cancer	1.58e-05	4.39e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	1.56e-05	4.35e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HIF1A—esophageal cancer	1.56e-05	4.34e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.55e-05	4.32e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.54e-05	4.3e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NOS3—esophageal cancer	1.54e-05	4.28e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.53e-05	4.27e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.53e-05	4.27e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB2—esophageal cancer	1.52e-05	4.25e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KDR—esophageal cancer	1.52e-05	4.23e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NOS3—esophageal cancer	1.52e-05	4.22e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GNG7—esophageal cancer	1.51e-05	4.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.5e-05	4.19e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—HMOX1—esophageal cancer	1.5e-05	4.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KDR—esophageal cancer	1.49e-05	4.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KDR—esophageal cancer	1.49e-05	4.15e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.47e-05	4.1e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCND1—esophageal cancer	1.46e-05	4.08e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—PIK3CA—esophageal cancer	1.46e-05	4.08e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—PIK3CA—esophageal cancer	1.44e-05	4.02e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.44e-05	4.01e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB2—esophageal cancer	1.44e-05	4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCND1—esophageal cancer	1.43e-05	3.99e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	1.43e-05	3.98e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—EP300—esophageal cancer	1.42e-05	3.97e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB2—esophageal cancer	1.42e-05	3.95e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.42e-05	3.95e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	1.42e-05	3.95e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCND1—esophageal cancer	1.41e-05	3.93e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.41e-05	3.93e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.41e-05	3.92e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.41e-05	3.92e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.4e-05	3.91e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.4e-05	3.89e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.39e-05	3.88e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CDKN1A—esophageal cancer	1.39e-05	3.86e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.37e-05	3.82e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CDKN1A—esophageal cancer	1.36e-05	3.8e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.36e-05	3.79e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.35e-05	3.77e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.35e-05	3.75e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EP300—esophageal cancer	1.35e-05	3.75e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCND1—esophageal cancer	1.35e-05	3.75e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.34e-05	3.74e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.33e-05	3.71e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EP300—esophageal cancer	1.32e-05	3.68e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.31e-05	3.64e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CDKN1A—esophageal cancer	1.3e-05	3.63e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EP300—esophageal cancer	1.3e-05	3.62e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.3e-05	3.61e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.28e-05	3.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.27e-05	3.55e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.27e-05	3.54e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.27e-05	3.54e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCND1—esophageal cancer	1.27e-05	3.54e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.26e-05	3.52e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ENO1—esophageal cancer	1.26e-05	3.52e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCND1—esophageal cancer	1.25e-05	3.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.25e-05	3.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.25e-05	3.48e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PSME2—esophageal cancer	1.24e-05	3.47e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PSME1—esophageal cancer	1.24e-05	3.47e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EP300—esophageal cancer	1.24e-05	3.45e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	1.23e-05	3.42e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.22e-05	3.39e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	1.21e-05	3.38e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.2e-05	3.35e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—EP300—esophageal cancer	1.2e-05	3.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.2e-05	3.34e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.2e-05	3.33e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.19e-05	3.33e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—esophageal cancer	1.17e-05	3.27e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.17e-05	3.26e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EP300—esophageal cancer	1.17e-05	3.26e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.16e-05	3.23e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—esophageal cancer	1.15e-05	3.21e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—esophageal cancer	1.15e-05	3.2e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.15e-05	3.2e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.15e-05	3.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.14e-05	3.18e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.14e-05	3.17e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—NOS3—esophageal cancer	1.14e-05	3.17e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—esophageal cancer	1.13e-05	3.15e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—esophageal cancer	1.12e-05	3.13e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.11e-05	3.1e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—esophageal cancer	1.11e-05	3.08e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.11e-05	3.08e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.09e-05	3.03e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.09e-05	3.02e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.09e-05	3.02e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—esophageal cancer	1.08e-05	3.01e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NOS3—esophageal cancer	1.08e-05	3e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.07e-05	2.99e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.07e-05	2.97e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.07e-05	2.97e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—esophageal cancer	1.06e-05	2.94e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PIK3CA—esophageal cancer	1.05e-05	2.94e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.04e-05	2.9e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—esophageal cancer	1.02e-05	2.84e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.01e-05	2.82e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.01e-05	2.81e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—esophageal cancer	1.01e-05	2.8e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	9.97e-06	2.78e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—esophageal cancer	9.97e-06	2.78e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—esophageal cancer	9.84e-06	2.74e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—esophageal cancer	9.83e-06	2.74e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CREBBP—esophageal cancer	9.83e-06	2.74e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	9.76e-06	2.72e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—esophageal cancer	9.65e-06	2.69e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	9.61e-06	2.68e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CREBBP—esophageal cancer	9.6e-06	2.67e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—esophageal cancer	9.59e-06	2.67e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—esophageal cancer	9.45e-06	2.63e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—esophageal cancer	9.44e-06	2.63e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—esophageal cancer	9.42e-06	2.62e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—esophageal cancer	9.29e-06	2.59e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	9.28e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMOX1—esophageal cancer	9.22e-06	2.57e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	9.17e-06	2.55e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	9.13e-06	2.54e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	9.11e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.04e-06	2.52e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CREBBP—esophageal cancer	8.96e-06	2.5e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—esophageal cancer	8.87e-06	2.47e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PIK3CA—esophageal cancer	8.86e-06	2.47e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.85e-06	2.46e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—esophageal cancer	8.83e-06	2.46e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NOS3—esophageal cancer	8.8e-06	2.45e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—esophageal cancer	8.69e-06	2.42e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—esophageal cancer	8.67e-06	2.41e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.67e-06	2.41e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—esophageal cancer	8.66e-06	2.41e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	8.65e-06	2.41e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NOS3—esophageal cancer	8.59e-06	2.39e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	8.53e-06	2.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—esophageal cancer	8.37e-06	2.33e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—esophageal cancer	8.26e-06	2.3e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—esophageal cancer	8.18e-06	2.28e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NOS3—esophageal cancer	8.1e-06	2.25e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—esophageal cancer	8.05e-06	2.24e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NOS3—esophageal cancer	8.03e-06	2.24e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—esophageal cancer	7.86e-06	2.19e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—esophageal cancer	7.69e-06	2.14e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CREBBP—esophageal cancer	7.66e-06	2.13e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—esophageal cancer	7.57e-06	2.11e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—esophageal cancer	7.55e-06	2.1e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—esophageal cancer	7.52e-06	2.1e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.4e-06	2.06e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—esophageal cancer	7.4e-06	2.06e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—esophageal cancer	7.39e-06	2.06e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—esophageal cancer	7.34e-06	2.04e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NOS3—esophageal cancer	6.86e-06	1.91e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—esophageal cancer	6.7e-06	1.86e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—esophageal cancer	6.54e-06	1.82e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	6.53e-06	1.82e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	6.43e-06	1.79e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	6.41e-06	1.79e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PIK3CA—esophageal cancer	6.41e-06	1.78e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—esophageal cancer	6.32e-06	1.76e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—esophageal cancer	6.27e-06	1.75e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—esophageal cancer	6.22e-06	1.73e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—esophageal cancer	6.2e-06	1.73e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—esophageal cancer	6.16e-06	1.72e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—esophageal cancer	6.11e-06	1.7e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PIK3CA—esophageal cancer	6.05e-06	1.69e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.91e-06	1.65e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NOS3—esophageal cancer	5.29e-06	1.47e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—esophageal cancer	5.22e-06	1.45e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.95e-06	1.38e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.84e-06	1.35e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.83e-06	1.35e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.56e-06	1.27e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.52e-06	1.26e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—esophageal cancer	4.03e-06	1.12e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.86e-06	1.07e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.98e-06	8.3e-06	CbGpPWpGaD
